Product Name: EGFR (1169-1175) pY1172
Product Number: PE-04AFX95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: EGFR (1169-1175) pY1172

Product Use: Services as a blocking peptide for use with the EGFR-pY1172 rabbit polyclonal antibody (Cat. No.: AB-PK601) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminal of the kinase after the catalytic domain. Y1172 phosphorylation stimulates phosphotransferase activity. Phosphorylation regulates cell growth, protein degradation, receptor internalization, and molecular association.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: NPD-pY-QQD

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1133.01 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: EGFR - pY1172 phosphosite-specific antibody (Cat. No.: AB-PK601)

Scientific Background: EGFR (ERBB1, HER1) is a protein-tyrosine kinase of the TK group and EGFR family. EGFR regulates cell proliferation, division, motility, survival, and has other roles in tissue development. It is activated by binding epidermal growth factor (EGF) and transforming growth factor-alpha (TGFa), which induce dimerization and autophosphorylation. Phosphorylation of Y270 stimulates interaction with EGFR. Phosphorylation of Y869 increases phosphotransferase activity and induces interaction with COX2. Phosphorylation of Y1016 increases phosphotransferase activity and induces interaction with GrbB2, PLCg1, PTPN11 (SHP2), RasGAP, and Vav2. Phosphorylation of Y1069 increases phosphotransferase activity and induces interaction with Cbl. Phosphorylation of Y1092 induces interaction with PLCg1, PTPN6 (SHP1) and Ras-GAP. Phosphorylation of Y1110 induces interaction with Ras-GAP. Phosphorylation of Y1172 increases phosphotransferase activity and induces interaction with Dok1, EGFR, RasGAP, PTPN11 (SHP2), and Vav2. Phosphorylation of Y1197 increases phosphotransferase activity and induces interaction with Cbl, EGR, PLCg1, RasGAP, SH3KBP1, Shc1, and PTPN6 (SHP1). EGFR is inhibited by phosphorylation at T678,S695 and S1026. Phosphorylation of T693, S695, S1070, S1071, and S1190 contributes to receptor internalization. EGFR is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. Constitutive activation of EGFR kinase activity has been seen with the mutations of V689M, E1005R+D1006K. The active form of the protein kinase normally acts to promote tumour cell proliferation.